Prevention of Mother‐to‐child Transmission of Hepatitis B Virus by Treating Mothers with High Viral Loads

Yihua Zhou

DOI: https://doi.org/10.1002/hep.28619

IF: 17.298

2016-01-01

Hepatology

Abstract:mild disease unless injecting duration until cessation is prolonged or they have significant HIV coinfection. This is contrary to evidence that suggests prioritizing PWID for early treatment is cost-effective in settings with <60% chronic HCV among PWID—but of course, while HCV treatment costs remain high, targeting people with severe disease is the first priority. Second, the restriction of treatment to patients with F3/F4 and patients with over 3 months remaining on their sentence will limit the effective treatment rate, potentially reducing the cost-effectiveness of the optout testing program. This is illustrated in the Italian data, where only 29 patients were treated with DAAs out of a total of 191 chronic infections, because many patients were not eligible for DAA therapy. Overall, we are encouraged by the high success of the HCV testing programs in the Italian prisons reported in this study and the clear efforts to achieve completion, sustained viral response, and continuity of care among patients who are eligible for HCV DAA treatment. Additional data on uptake and outcomes among PWID would enable quantification of the impact and cost-effectiveness of such a strategy, including both individual benefits (on liver disease progression) and population benefits (on prevention of HCV transmission).